Acute and Sub-Acute Oral Toxicity Studies of Hydroalcoholic Extract of Terminalia arjuna (Roxb.) Bark in Rodents


  • Alex Thomas Dept. of Chemistry, School of Advanced Sciences, VIT Vellore, 632014. India
  • Ethiraj K. Radhakrishnan Dept. of Chemistry, School of Advanced Sciences, VIT Vellore, 632014. India


Rat, No-Observed-Adverse-effect Level, LD50, Terminalia arjuna bark extract


Terminalia arjuna (T.arjuna) bark is extensively used by Indian herbal medicine practitioners for treating various cardiovascular ailments. Though multiple clinical trials and non-clinical studies have been reported on T.arjuna bark, the toxicology data was found to be inadequate. Hence, studies were conducted to establish the toxicology profile of T.arjuna bark. In the acute toxicity study, animals were administered with a single dose of 2000 mg/kg of T. arjuna bark hydroalcoholic extract, whereas in repeated dose toxicity study animals were administered with the extract at doses of 0, 100, 500, and 1000 mg/kg, once daily, for 28 consecutive days, and on day 29, all the animals were humanely sacrificed after the collection of required blood samples. There were no mortality or clinical signs of toxicity observed after administration of a single dose of 2000 mg/kg of T. arjuna bark hydro-alcoholic extract. In the repeated dose toxicity study, there were no treatment-related adverse effects in any of the dose groups and control group animals in respect to clinical signs, body weight, feed consumption, haematology, clinical chemistry, urinalysis, and histopathology. Based on the results, LD50 of T. arjuna bark hydro-alcoholic extract is concluded as >2000 mg/kg. No-Observed-Adverse-effect Level of T. arjuna bark hydroalcoholic extract from 28-day repeated dose toxicity study is established at 1000 mg/kg/day. 


Junhua Z, Igho JA, Paul P, Mohamed E. The safety of herbal medicine: from prejudice to evidence. Evid Based Complementary Altern Med. 2015; 1–3.

Augustine A, Sreeraj G. Medicinal properties of Terminalia arjuna (Roxb.) Wight & Arn.: A review. J Tradit Complement Med. 2016; 1-14.

Mohan MT, Anand T, Pratiksha VB, Uma MD, Babusha, ST, and Farhath K. Terminalia arjuna extract attenuates

isoproterenol-induced cardiac stress in Wister rats via an Anti-Apoptotic Pathway. Proc Natl Acad Sci India Sect B

Biol Sci. 2020; 1-12.

Gupta S, Bishnoi JP, Kumar N, Kumar H, and Nidheesh T. Terminalia arjuna (Roxb.) Wight &Arn.: Competent source of bioactive components in functional food and drugs. Pharma Innov. 2018; 7(3):223-231.

Kalem IK, Bhat ZF, Kumar S, Desai A. Terminalia arjuna: A novel natural preservative for improved lipid oxidative stability and storage quality of muscle foods. Food Sci Hum Wellness. 2017; 6(4):167-175.

Beigi M, Haghani E, Alizadeh A, Samani ZN. The pharmacological properties of several species of Terminalia in the world. Int J Pharm Sci Res. 2018; 9(10): 4079-88.

Hetal A, Vivek B, Shukla VJ, Prajapati PK, Nariya MB. A notable review on terminalia Terminalia arjuna and its imperative ayurvedic formulations: an overview. Int Ayurvedic Med J. 2015; 3:1814-1821.

Divya G, Mukesh K. Evaluation of in vitro antimicrobial potential and GC–MS analysis of Camellia sinensis and Terminalia arjuna. Biotechnol Rep. 2016; (13), 19-25.

Gaurav K, Nikhat S, Santosh K, Subir KM, Sayeed A, Manish S, Shyamal KG. Transcriptomic validation of the protective effects of aqueous bark extract of Terminalia arjuna (Roxb.) on isoproterenol-induced cardiac hypertrophy in rats. Front Pharmaco. 2019; (10):1-12.

Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for Laboratory Animal Facility. Gaz India. 1998.

OECD. Test No. 423: Acute Oral toxicity - Acute Toxic Class Method. OECD Guidelines for the Testing of Chemicals, Section 4. (2002). Paris: OECD. 2002.

Schedule Y. Drugs and Cosmetics Rules, Appendix III, Single-dose Toxicity Studies: Drugs and Cosmetics Rules, 1945. (2005) Govt of India. 2005a.

OECD. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing of Chemicals, Section 4. (2008). Paris: OECD. 2008

Schedule Y. Drugs and Cosmetics Rules, 1945, Appendix III, Repeated-dose Systemic Toxicity Studies. (2005) Govt. of India. 2005b.

Dwivedi S, Chansouria JP, Somani PN, Udupa KN. Effect of Terminalia arjuna on ischaemic heart disease. Altern Med. 1989; 3:115–22.

Jain V, Poonia A, Agarwal RP, Panwar RB, Kochar DK, Mishra SN. Effect of Terminalia arjuna in patients of angina pectoris (A clinical trial). Indian Med Gaz. 1992; 36:56–9.

Verma SK,Bordia A. Effect of Terminalia arjuna bark (arjunchhal) in patients of congestive heart failure and hypertension. J Res and Ed Indian Med. 1988; 7:31–6.

Bharani A, Ganguly A, Bhargave KD. Salutary effect of Terminalia arjuna in patients with severe refractory heart

failure. Int J Cardiol. 1995; 49(3):191-9.

Antani JA, Gandhi S, Antani NJ. Terminalia arjuna in congestive heart failure. J Assoc Physicians India. 1991; 39:801.

Pingali U, Fatima N, Nizampatnam M. Evaluation of Terminalia arjuna on cardiovascular parameters and platelet aggregation in patients with Type II diabetes mellitus. Res JLife Sci Res. 2013; 1:7–12.

Tripathi VK, Singh B, Jha RN, Pandey VB, Udupa KN. Studies on Arjuna in coronary heart disease. J Res Ayurveda and Siddha. 2000; 21:37–40.

Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study. Ayu. 2012; 33(2):197-201.

Shin JW, Seol IC, Son CG. Interpretation of animal dose and human equivalent dose for drug development. J Korean Ori Med Sci. 2010; 31:3.

Agu KC, Okolie NP, Eze I, Anionye JC, Falodun A. Phytochemical analysis, toxicity profile, and hemomodulatory properties of Annona muricata (Soursop). Egypt J Haematol 2017; 42:36-44.

Ugwah-Oguejiofor CJ, Okoli CO, Ugwah MO, Umaru ML, Ogbulie CS, Mshelia HE, Umar M, Njan AA. Acute and subacute toxicity of aqueous extract of aerial parts of Caralluma dalzielii N. E. Brown in mice and rats. Heliyon. 2019; 5 (1):1-120.

Dwivedi S, Chopra D. Revisiting Terminalia arjuna – An Ancient Cardiovascular Drug. J Tradit Complement Med. 2014; 4(4): 224–231.

Wherly PH, Daniel KN,Robert BL. Analysis of Rodent Growth Data in Toxicology Studies. Toxicol Sci. 2002; 66 (2): 313–319.

Ibrahim HS, Abdullah RA, Abdullah HY, Sani M. Acute and Sub-Chronic Toxicity Studies on the Methanol Leaf Extract of Leptadenia hastata in Wistar Rats. Trop J Nat Prod Res. (10), 302–306.

Arika WM, Nyamai DW, Musila MN, Ngugi MP, Njagi, ENM. Hematological markers of in vivo toxicity. J Hem &

Thromb Dis. 2016; 4 (2):1-7.

Everds NE. Evaluation of clinical pathology data: correlating changes with other study data. Toxicol Pathol 2015; 43(1):


Huang XJ, Choi YK, Im HS, Yarimaga O, Yoon E, Kim HS. Aspartate aminotransferase (AST/GOT) and alanine

aminotransferase (ALT/GPT) detection techniques. Sens 2006; 6(7): 756–782.

Kalakonda A, Jenkins BA, John S. Physiology, bilirubin. in: stat pearls. treasure island (FL): StatPearls. 2021.Rivadeneyra-Domínguez E, Becerra-Contreras Y, Vázquez-Luna A, Díaz-Sobac R, Rodríguez-Landa JF. Alterations of blood chemistry, hepatic and renal function, and blood cytometry in acrylamide-treated rats. Toxicol Rep. 2018; 5:1124-1128



How to Cite

Thomas, A., & Radhakrishnan, E. K. (2023). Acute and Sub-Acute Oral Toxicity Studies of Hydroalcoholic Extract of Terminalia arjuna (Roxb.) Bark in Rodents: Tropical Journal of Natural Product Research (TJNPR), 7(7), 3351–3359. Retrieved from